Aminoglycosides: pre-treatment screening advice on genetic testing for aminoglycoside exposure posing risk to hearing (advice in relevant monographs; see example in gentamicin). Vaccines update: restructure of Influenza vaccine monograph—creation of monographs for influenza vaccine (live) and influenza vaccine (inactivated). Kendall, MJ (2009). "Chairman of the Joint Formulary Committee, British National Formulary". Clinical Medicine. 9 (4): 349–352. doi: 10.7861/clinmedicine.9-4-349. PMC 4952503. PMID 19728509. This update contains 7 significant changes, 2 dose changes, 2 new monographs, 1 new preparation, and 1 deleted monograph. Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in the coming months [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate).

This was an anomaly, [4] as in relation to responses to medicines, the difference between a newborn and a sixteen-year-old is greater than the difference between a sixteen-year-old and a sixty-year-old. Starting in 2002, Prof Martin Kendall, [5] [6] then chairman of the BNF Joint Formulary Committee worked to get things changed.

Clarithromycin [update to include dosing for prevention of invasive group A streptococcal infection in children from 6 months old and adults].

The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. VNRAS.com. "BNF for Children BNFC 2019-2020" (PDF). Archived from the original (PDF) on 11 October 2021 . Retrieved 1 May 2022. Elias-Jones, A.; Rylance, G. (2005). "The launch of the British National Formulary for Children". Archives of Disease in Childhood. 90 (10): 997–998. doi: 10.1136/adc.2005.080366. PMC 1720111. PMID 16177154. The entries are classified by group of drug, giving cautions for use, side effects, indications and dose for most of the drugs available for children in the UK National Health Service. It also includes information on the unlicensed uses of certain drugs. Though published in and for the United Kingdom, the vast bulk of the clinical information will apply in any country.

The BNF also includes the Nurse Prescribers' Formulary (NPF) and other NPF content for use by District Nurses and Specialist Community Public Health Nurses (including Health Visitors), who have received training to become nurse prescribers. [19] Sister publications [ edit ] Ceftriaxone [update to include dosing in children from 12 years old for gonococcal conjunctivitis, gonococcal epididymo-orchitis, and disseminated gonococcal infection]. It is used by pharmacists and doctors (both general practitioners (GPs) and generalist hospital practitioners, and by other prescribing healthcare professionals (such as nurses, pharmacy technicians, paramedics, and dentists); as a reference for correct dosage, indication, interactions and side effects of drugs. It is also used as a reassurance by those administering drugs, for example a nurse on a hospital ward, and even for patients and others seeking an authoritative source of advice on any aspect of pharmacotherapy. Genital system infections, antibacterial therapy: addition of an overview section, and updated guidance for the management of syphilis.

Rabies vaccine [update to pre-exposure immunisation booster dose in patients who may have frequent, unrecognised exposures e.g. bat handlers].

Hyoscine hydrobromide patches (Scopoderm® 1.5 mg patch or Scopoderm® TTS patch): risk of anticholinergic side effects, including hyperthermia [MHRA/CHM advice]. Valproate: re-analysis of study on risks in children of men taking valproate [MHRA/CHM advice] (advice in sodium valproate, valproic acid; see example in sodium valproate). Morphine: important safety information updated to highlight availability of different strengths of oral solution.

Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality [MHRA/CHM advice] (advice in abrocitinib, tofacitinib, upadacitinib; see example in tofacitinib). Direct-acting oral anticoagulants (DOACs): paediatric formulations [MHRA/CHM advice] (advice in rivaroxaban). chairing the Paediatric Formulary Committee and Dinesh Mehta as the first executive editor. Anne, the Princess Royal attended the launch on 14 July.Cefotaxime [update to dosing for uncomplicated gonorrhoea, and update to include dosing in children from 12 years old for disseminated gonococcal infection]. NICE apps for smartphones and tablets". www.nice.org.uk. National Institute for Health and Care Excellence. April 2014. Archived from the original on 13 August 2014 . Retrieved 19 July 2014. Drugs that cause thromboembolism: pharmacodynamic effects drug group deleted from Appendix 1 interactions. Wade, O. L. (1993). "British National Formulary: Its birth, death, and rebirth". BMJ (Clinical Research Ed.). 306 (6884): 1051–1054. doi: 10.1136/bmj.306.6884.1051. PMC 1676980. PMID 8490505.